RedHill Biopharma is dedicated to the commercialization and development in the U.S. of proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, including cancer

Development Pipeline

RedHill's pipeline of  late-stage, proprietary development programs includes three Phase 3 programs for gastrointestinal disease, as well as several Phase 2 programs in oncology and gastrointestinal diseases. 

Please see RedHill Biopharma's expanded acceess program here.

Commercial Products

RedHill has assembled an experienced specialty GI commercial team, with a proven track-record, to lead its U.S. commercial operations, headquartered in Raleigh, NC. RedHill promotes a gastrointestinal specialty product in select U.S. territories: 

Aemcolo® (rifamycin) – prescription drug

RedHill plans to launch one additional approved prescription drug in the U.S.:

Talicia® (omeprazole, amoxicillin and rifabutin) – prescription drug